Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: beyond autoimmune insulin-dependent diabetes

AIMS: Immune-mediated beta cell destruction is known to cause hyperglycemia in patients receiving immune checkpoint inhibitor (ICI) cancer therapy. However, it is uncommon, and little is known about the full spectrum of hyperglycemia in patients receiving ICIs. We aimed to characterize the prevalenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Res Clin Pract
Main Authors: Leiter, Amanda, Carroll, Emily, Brooks, Danielle, Shimol, Jennifer Ben, Eisenberg, Elliot, Wisnivesky, Juan P., Galsky, Matthew D., Gallagher, Emily J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940559/
https://ncbi.nlm.nih.gov/pubmed/33347896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.diabres.2020.108633
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados